Global Leading Market Research Publisher QYResearch announces the release of its latest report ”Neurodegenerative Disease CDMO – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″ . Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Neurodegenerative Disease CDMO market, including market size, share, demand, industry development status, and forecasts for the next few years.
For pharmaceutical research and development executives, biotech chief scientific officers, and investors allocating capital across the central nervous system therapeutic space, the neurodegenerative disease drug development landscape presents a uniquely challenging risk-reward calculus. Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis collectively affect an estimated 50 million people worldwide, a figure projected to double by 2050 as global populations age, yet the therapeutic arsenal remains profoundly inadequate. The drug development failure rate for neurodegenerative indications exceeds 99% from first-in-human studies to regulatory approval, driven by the convergence of incompletely understood disease mechanisms, the inaccessibility of target tissue for biopsy-based biomarker validation, the protracted natural history requiring clinical trials of unprecedented duration, and the formidable challenge of achieving therapeutic concentrations across the blood-brain barrier. Faced with this capital intensity and scientific complexity, pharmaceutical sponsors are increasingly outsourcing specialized development and manufacturing functions to contract development and manufacturing organizations with dedicated neuroscience expertise. The neurodegenerative disease CDMO —a contract research, development, and manufacturing organization that focuses on the field of neurodegenerative diseases and provides pharmaceutical companies and scientific research institutions with a full range of services from drug discovery, preclinical research to commercial production—has emerged as an essential partner in the quest to develop disease-modifying therapies for these devastating conditions. Drawing on proprietary market intelligence from Global Info Research , the global neurodegenerative disease CDMO market was valued at USD 770 million in 2025 and is projected to reach USD 1,220 million by 2032 , advancing at a compound annual growth rate (CAGR) of 6.9% from 2026 to 2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6089301/neurodegenerative-disease-cdmo
Service Definition and Technology Platform Architecture
The core mission of a neurodegenerative disease CDMO is to develop innovative therapies for the complex pathologies of diseases such as Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease—including abnormal protein aggregation, neuroinflammation, and mitochondrial dysfunction—by integrating professional technology platforms such as neuroscience, protein engineering, cell therapy, and gene therapy. The CDMO also relies on a deep understanding of the special requirements of regulatory agencies such as the FDA and EMA, including biomarker verification and long-term safety assessment, to ensure that research and development and production meet international standards, ultimately accelerating the launch of drugs for the treatment of neurodegenerative diseases. This regulatory expertise constitutes a critical competitive differentiator, as the evolving guidance from the FDA’s Center for Drug Evaluation and Research on demonstrating efficacy in early Alzheimer’s disease through biomarker endpoints—specifically amyloid beta reduction demonstrated via positron emission tomography imaging—requires CDMO partners to possess not merely manufacturing capability but also bioanalytical method development and validation proficiency.
Technology Segmentation: Therapeutic Modality-Specific Capabilities
The neurodegenerative disease CDMO market is segmented by therapeutic modality into small molecule drug CDMO services, biopharmaceutical CDMO services encompassing monoclonal antibodies and recombinant proteins targeting pathological protein aggregates, cell and gene therapy CDMO services, and other specialized platforms. The cell and gene therapy segment represents the fastest-growing domain, driven by the proliferation of adeno-associated virus vector-based gene replacement strategies for monogenic conditions including spinal muscular atrophy and the expansion of antisense oligonucleotide platforms for conditions including Huntington’s disease and certain forms of amyotrophic lateral sclerosis.
Application Segmentation: Disease-Specific Expertise
Application segmentation spans Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis, multiple system atrophy, progressive supranuclear palsy, and other neurodegenerative conditions. Alzheimer’s disease commands the largest development pipeline and corresponding CDMO service demand, driven by the continued commercial success of anti-amyloid monoclonal antibody therapies and the intensifying research investment in tau-targeted approaches.
Manufacturing and Service Delivery Paradigm
The CDMO service model exemplifies a project-based service delivery paradigm distinct from both discrete manufacturing and continuous process industries . Each client engagement represents a unique project with customized scope, timeline, and deliverables. The manufacturing operations within a CDMO—whether small molecule active pharmaceutical ingredient synthesis, biologic drug substance production in single-use bioreactors, or viral vector manufacturing—operate as discrete batch processes governed by current Good Manufacturing Practice regulations. Key market participants include AC Immune, Alterity Therapeutics, Biogen, Charles River Laboratories, Coave Therapeutics, Sysmex Corp, Eisai, Fujirebio Holdings, GenSight Biologics, Neuropore Therapies, Nevrargenics, PPD, Samsung Biologics, and Sanofi (Vigil Neuroscience) .
Strategic Outlook
The neurodegenerative disease CDMO industry outlook through 2032 reflects sustained pharmaceutical industry investment in neuroscience drug development, the increasing reliance of emerging biotech companies on outsourced development and manufacturing infrastructure, and the expanding regulatory pathway for accelerated approval based on surrogate biomarker endpoints. The 6.9% CAGR reflects both volume growth in outsourced services and value migration toward higher-complexity modalities including cell and gene therapy manufacturing that command premium pricing relative to traditional small molecule services.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
